Increasing rates of in vitro resistance to ciprofloxacin and norfloxacin in isolates from urine specimens.
作者信息
Desgrandchamps D, Munzinger J
出版信息
Antimicrob Agents Chemother. 1989 Apr;33(4):595-6. doi: 10.1128/AAC.33.4.595-b.
Abstract
摘要
相似文献
1
Increasing rates of in vitro resistance to ciprofloxacin and norfloxacin in isolates from urine specimens.
Antimicrob Agents Chemother. 1989 Apr;33(4):595-6. doi: 10.1128/AAC.33.4.595-b.
2
Comparative in vitro activity of ciprofloxacin, ofloxacin and pefloxacin against resistant clinical isolates.
Chemioterapia. 1987 Apr;6(2):75-8.
3
[Increase in the frequency of norfloxacin and ciprofloxacin resistance of bacteria isolated from urine culture].
Rev Assoc Med Bras (1992). 1998 Jul-Sep;44(3):196-200. doi: 10.1590/s0104-42301998000300006.
4
Activity of ciprofloxacin against resistant clinical isolates.
J Antimicrob Chemother. 1986 Mar;17(3):281-6. doi: 10.1093/jac/17.3.281.
5
The comparative in-vitro activity of norfloxacin, ciprofloxacin, enoxacin and nalidixic acid against 423 strains of gram-negative rods and staphylococci isolated from infected hospitalised patients.
J Antimicrob Chemother. 1986 Jan;17(1):63-7. doi: 10.1093/jac/17.1.63.
6
Norfloxacin, ciprofloxacin, and ofloxacin: current clinical roles.
Curr Clin Top Infect Dis. 1989;10:194-240.
7
In vitro and in vivo antibacterial activities of E-4497, a new 3-amine-3-methyl-azetidinyl tricyclic fluoroquinolone.
Antimicrob Agents Chemother. 1991 Mar;35(3):442-7. doi: 10.1128/AAC.35.3.442.
8
Bacterial profile and antimicrobial susceptibility patterns in chronic suppurative otitis media at the University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia.
BMC Res Notes. 2019 Jul 15;12(1):414. doi: 10.1186/s13104-019-4452-4.
9
Development of resistance in Pseudomonas aeruginosa to imipenem, norfloxacin, and ciprofloxacin during therapy: proof provided by typing with a DNA probe.
J Infect Dis. 1988 Apr;157(4):743-8. doi: 10.1093/infdis/157.4.743.
10
Fleroxacin: in-vitro activity worldwide against 20,807 clinical isolates and comparison to ciprofloxacin and norfloxacin.
J Antimicrob Chemother. 1988 Oct;22 Suppl D:3-17. doi: 10.1093/jac/22.supplement_d.3.
引用本文的文献
1
Outpatient Antibiotic Consumption for Urinary Infections in Croatia 2005 - 2014: What can be Learned from Utilization Trends.
Zdr Varst. 2018 Oct 1;57(4):183-191. doi: 10.2478/sjph-2018-0023. eCollection 2018 Dec.
2
Increasing incidence of Corynebacterium group D2 strains resistant to norfloxacin and ciprofloxacin.
Eur J Clin Microbiol Infect Dis. 1989 Dec;8(12):1117-8. doi: 10.1007/BF01975179.
3
Persistence mechanisms in Pseudomonas aeruginosa from cystic fibrosis patients undergoing ciprofloxacin therapy.
Antimicrob Agents Chemother. 1991 Aug;35(8):1538-46. doi: 10.1128/AAC.35.8.1538.
本文引用的文献
1
Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations.
Antimicrob Agents Chemother. 1984 Jun;25(6):775-7. doi: 10.1128/AAC.25.6.775.
2
Oral ciprofloxacin in resistant urinary tract infections.
Am J Med. 1987 Apr 27;82(4A):303-6.
3
Ciprofloxacin therapy in complicated urinary tract infections caused by Pseudomonas aeruginosa and other resistant bacteria.
J Antimicrob Chemother. 1986 Nov;18 Suppl D:117-21. doi: 10.1093/jac/18.supplement_d.117.
4
Comparison of ciprofloxacin and co-trimoxazole in the treatment of uncomplicated urinary tract infection in women.
J Antimicrob Chemother. 1986 Nov;18 Suppl D:103-6. doi: 10.1093/jac/18.supplement_d.103.
5
In-vitro selection of bacteria resistant to the 4-quinolone agents.
J Antimicrob Chemother. 1987 Jan;19(1):65-71. doi: 10.1093/jac/19.1.65.
6
Susceptibility of Hong Kong isolates of methicillin-resistant Staphylococcus aureus to antimicrobial agents.
J Antimicrob Chemother. 1988 May;21(5):581-8. doi: 10.1093/jac/21.5.581.
7
Ciprofloxacin therapy of respiratory tract infection with Pseudomonas aeruginosa.
Eur J Clin Microbiol Infect Dis. 1988 Oct;7(5):661-4. doi: 10.1007/BF01964247.
8
Development of resistance to nalidixic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacin.
Antimicrob Agents Chemother. 1988 Aug;32(8):1285-8. doi: 10.1128/AAC.32.8.1285.
9
Comparison of the Cobas-Bact five-hour susceptibility testing system with the NCCLS agar diffusion and dilution methods.
Eur J Clin Microbiol Infect Dis. 1988 Aug;7(4):511-7. doi: 10.1007/BF01962602.
Zotero 插件